WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Alcon Inc. ALC

NYSEMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
ALC financials
Moat score
70
ROIC
3.4%
P/E
53.5
Incl. −$229M one-offs
EV/EBIT
38.7
Incl. −$344M one-offs
FCF yield
4.7%
Dividend yield
0.5%
Market cap
$35.6B

Moat ranks

Score rankTied #243 of 396
Durabilitydurable
Market structureOligopoly
Pricing powermoderate

Balance sheet

9/30/26
$BDec 31Sep 30
Cash1.51.7
Securities0.10.1
Debt4.74.8
Net cash-3.1-3.0
Equity22.021.7
Leverage
Debt / EBITDA
2.17×
Debt / equity
0.22×
Leases (9/30/26)
$573M
Capital
Diluted shares
483M
Book value / share
$44.97
Price / book
1.6×
Net cash / share
−$6.12
Market cap
$35.6B
Enterprise value
$38.6B

Per-share record

Fiscal years and TTM
Scale
$0$10$20$30'16'17'18'19'20'21'22'23'2420.96'2522.73TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth4.7%-1.8 pts
Operating margin13.9%+1.2 pts
FCF margin22.4%+1.9 pts
Capex / revenue5.4%-1.8 pts
Consumables net sales$789M+6%
Surgical equipment and other net sales$269M+11%
Contact lenses net sales$737M+4%
Ocular health net sales$500M+8%
Surgical implantables net sales$422M-2%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About ALC

Alcon sells Surgical and Vision Care products. FY2025 revenue, including other revenue, was $10.401B, split 55.3% Surgical and 44.7% Vision Care.

Revenue mix
Surgical 55.3%Vision Care 44.7%
  • Installed Base Consumables

    Installed base of ophthalmic surgical equipment with multi-year replacement cycles helps pull recurring sales of procedure-linked consumables.

  • Brand Trust

    Brand familiarity and trust, reinforced by eye-care-professional recommendations, support premium positioning and customer retention across contact lenses and ocular health.

  • Capex Knowhow Scale

    Specialized material science, automation, and proprietary manufacturing know-how in contact lenses and ocular products benefit from scale and a global manufacturing footprint.

Timeline
  1. Oct 2, 2026

    Alcon reported a 256-patient study showing Systane Pro symptom relief was non-inferior to Miebo over one month. The short, company-funded study supports positioning but does not prove long-term superiority.

  2. Sep 30, 2026 · Gain +$58M

    IEEPA refunds: $55m reduction of cost of sales and $3m related interest reported in operating other income. $1m PP&E credit is excluded from profit adjustment.

  3. Sep 3, 2026

    Alcon launched Unity M, a modular surgical microscope with approvals across several major markets, expanding its surgical equipment offering and potential cross-selling.

  4. Aug 26, 2026

    Alcon priced EUR 500M of 3.875% notes due 2033 for general corporate purposes, potentially including refinancing; the debt extends funding availability but creates interest obligations.

  5. Aug 10, 2026

    Alcon increased its 2026 core margin and earnings growth guidance while keeping constant-currency sales growth at 5%-7%, supported by new products and manufacturing efficiency.

Financial record

Fiscal year2016201720182019202020212022202320242025TTMTrendChange 2016–25
Per share ($)
Revenue–13.9114.6515.3813.9716.8017.6319.0419.9220.9622.73–
Cash flow–2.492.341.881.682.732.462.804.174.584.86–
Earnings–0.52-0.46-1.34-1.090.760.681.962.051.981.38–
Free cash flow–1.480.880.500.520.33-0.031.082.833.243.45–
Capex–1.021.461.381.162.392.491.721.351.341.41–
Dividends–0.000.000.000.000.110.200.230.260.330.36–
Book value–47.1746.3739.5438.4939.0339.8041.5443.3244.4144.97–
Diluted shares (M)–488488488489493494497498496483–
Totals ($B)
Revenue6.66.87.27.56.88.38.79.59.910.411.0+5.2%/yr
Operating income0.0-0.1-0.2-0.2-0.50.60.71.01.41.41.0+72.6%/yr
Net income-0.20.3-0.2-0.7-0.50.40.31.01.01.00.7–
Free cash flow0.70.70.40.20.30.2-0.00.51.41.61.7+9.0%/yr
Buybacks0.00.00.00.00.00.00.00.00.00.70.9–
Dividends0.00.00.00.00.00.10.10.10.10.20.2–
Net cash–0.10.2-2.6-2.6-2.5-3.7-3.6-2.8-3.1-3.0–
Margins & returns (%)
Gross margin47.247.244.648.843.056.154.555.555.655.257.7+8.1 pts
Operating margin0.2-1.1-3.5-2.5-7.17.07.711.014.313.19.1+12.9 pts
Net margin-2.63.8-3.2-8.7-7.84.53.810.310.39.46.1+12.0 pts
FCF margin11.210.66.03.23.72.0-0.15.714.215.515.2+4.3 pts
ROIC–-0.3-0.9-0.7-1.92.22.43.64.84.53.4–
Return on equity-0.71.1-1.0-3.4-2.82.01.74.74.74.43.1+5.2 pts
R&D % of revenue7.68.68.28.79.810.28.18.88.89.513.1+2.0 pts
Stock pay % of revenue0.81.01.31.51.71.81.71.71.61.61.6+0.8 pts
Capex % of revenue7.77.310.09.08.314.214.19.06.86.46.2-1.3 pts

Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 16.9% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score70
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
moderate
Segments
  • Surgical55.3%
    1 claim
  • Vision Care44.7%
    2 claims

Moat claims

Applies to
Surgical
Confidence
Durability
durable
Trajectory
stableas of Nov 11, 2026
Why it holds

Installed base of ophthalmic surgical equipment with multi-year replacement cycles helps pull recurring sales of procedure-linked consumables. Implantable lens sales benefit from cross-selling but are not all tied to a proprietary console.

Why stable

Q3 2026 equipment and other sales were $269 million, up 11%, while consumables reached $789 million, up 6%. New equipment supports repeat supplies, but these sales do not distinguish replacement from incremental placements or prove a wider competitive lead.

Indicators
  • Consumables net sales$789M+6%
  • Surgical equipment and other net sales$269M+11%
  • Surgical implantables net sales$422M-2%
Risks
  • Competitors win new platform placements
  • Hospital multi-sourcing reduces pull-through
  • Pricing pressure from GPOs and tenders
  • Procedure volume sensitivity to reimbursement or macro shocks

Profile change log

  1. Oct 8, 2026 · business change

    Alcon reported a 256-patient study showing Systane Pro symptom relief was non-inferior to Miebo over one month. The short, company-funded study supports positioning but does not prove long-term superiority.

  2. Oct 8, 2026 · business change

    Alcon launched Unity M, a modular surgical microscope with approvals across several major markets, expanding its surgical equipment offering and potential cross-selling.

  3. Oct 8, 2026 · business change

    Alcon priced EUR 500M of 3.875% notes due 2033 for general corporate purposes, potentially including refinancing; the debt extends funding availability but creates interest obligations.

  4. Oct 8, 2026 · business change

    Alcon increased its 2026 core margin and earnings growth guidance while keeping constant-currency sales growth at 5%-7%, supported by new products and manufacturing efficiency.

  5. Oct 8, 2026 · business change

    Alcon discontinued the PowerVision lens programs after inconsistent patient outcomes. A $505M impairment, $103M release of purchase obligations and $115M tax benefit reduced reported Q2 earnings but did not consume cash at closure.

  6. Oct 8, 2026 · business change

    Alcon and RxSight agreed to develop adjustable presbyopia-correcting lenses through a non-exclusive license, with a $60M upfront payment and up to $140M of milestones. Alcon will lead commercialization; clinical success is still unproved.

  7. Oct 8, 2026 · business change

    Alcon and LENSAR terminated their merger after FTC opposition, blocking the planned addition of femtosecond cataract laser technology.

  8. Oct 8, 2026 · business change

    Alcon terminated its proposed STAAR Surgical acquisition after shareholders rejected the transaction, leaving the planned implantable contact lens expansion unrealized.

  9. Oct 8, 2026 · business change

    Alcon recalled certain Custom Pak surgical packs for incomplete seals; the FDA classified the recall as Class I, making packaging quality a concrete risk to surgeon trust.

  10. Oct 8, 2026 · analyst revision

    Verified the existing three moat claims and segment weights; added their trajectories, debate, management and two end markets. Removed inferred 40%-43% Surgical and 19%-21% Vision Care share ranges because rounded market sizes do not establish precise shares. Moat strengths and segment evidence status are unchanged.

  11. Oct 8, 2026 · analyst revision

    Rechecked the surgical installed-base advantage against the latest sales and competition evidence. Changed its trajectory from widening to stable because equipment revenue does not establish net placements or a growing competitive lead. Kept all moat strengths and segment evidence status. Limited the end-market leader lists to Alcon, the only company this source ranks across both complete global markets.

  12. Oct 8, 2026 · analyst revision

    Changed segment weights from first-half 2026 net sales to FY2025 total segment revenue, including other revenue, as reported in annual Note 4. Surgical changed from 55.4234% to 55.3216% and Vision Care from 44.5766% to 44.6784%. Removed contribution-profit shares because they exclude $1.081B of unallocated costs and do not reconcile to group operating profit.

  13. Oct 8, 2026 · business change

    Alcon divested and licensed selected product rights in China to Ocumension for equity and future royalties, recognizing a $57M gain and changing the sales base for later comparisons. Source: 2025 Form 20-F, February 24, 2026, Note 21.3.

  14. Oct 8, 2026 · business change

    Alcon acquired the remaining LumiThera equity for $124M net of acquired cash, adding the Valeda light-based treatment for dry age-related macular degeneration. Future payments can include up to $660M of commercial and $30M of development milestones. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.

  15. Oct 8, 2026 · business change

    Alcon acquired a controlling interest in Aurion for $496M net of acquired cash, reaching 99% of outstanding equity and adding a corneal cell therapy candidate. Clinical and regulatory outcomes will determine its value. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.

  16. Oct 8, 2026 · business change

    Alcon acquired the remaining Cylite equity for $72M net of acquired cash, adding cataract diagnostic technology to its surgical portfolio. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianALC
No peer numbers yet

Peers appear on the map as their numbers are collected.

Global ophthalmic surgical devices

As of Oct 8, 2026
OligopolyMedium cyclicalityUSD 14B in 2025

Manufacturer sales of ophthalmic implantables, consumables and surgical equipment, including associated technical and clinical service, support and training. Includes cataract, vitreoretinal, glaucoma and refractive procedures; excludes spectacle retail and hospital procedure fees.

  1. Alcon
2025 leaders, no comparable shares · Alcon 2025 Form 20-F
StocksMoatGross m.Op. m.
ALC7057.7%9.1%
Industry median147552.1%13.3%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Ageing populations increase cataract and retinal disease, supporting procedure demand beyond the economic cycle.
  • Long equipment replacement cycles support repeat consumables; faster, reliable procedures can win system placements.
  • Premium lenses and minimally invasive glaucoma treatments expand patient-paid product choices when clinical benefits are clear.
  • Access to surgeons, surgery centers and reimbursement determines whether unmet need becomes paid procedures.
Risks
  • Hospitals can postpone equipment purchases when financing costs rise; premium lens and refractive surgery spending is more sensitive to household budgets.
  • Reimbursement cuts, tenders and consolidation of providers can reduce supplier prices.
  • Clinical failures, sterility defects and recalls can reduce surgeon trust and erase development investment.
  • Tariffs and currencies affect global manufacturing costs and reported sales; competing platforms can disrupt incumbent consumable demand.

Bulls & bears

Key question · as of Oct 8, 2026

Can Unity equipment placements and new Vision Care products produce durable repeat sales and cash growth after launch spending, tariffs and failed development programs?

Arguments

3 forFaded: weakening or settled3 against

What to watch

  1. 1Surgical consumables and equipment net sales, including constant-currency growth
  2. 2Implantable lens net sales and competitive pressure
  3. 3Contact lens and ocular health net sales versus declines in legacy products
  4. 4Operating cash flow after gross equipment and intangible investment
  5. 5Tariff costs and reported profit versus recurring amortization and program closures

Next check: FY2026 results: verify product-launch conversion, efficiency costs and Neurotech integration; next earnings date unconfirmed.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 70/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ALC">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.